Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment. Take 2 mins to learn more.

News & Insights

Webinar Recording: Orthox

We recently held a webinar featuring a presentation from Dr Nick Skaer, CEO of portfolio company Orthox.

Orthox has developed FibroFix™, a silk-based technology for creating regenerative knee implants for patients with cartilage damage. The technology is based on a protein produced by the silk moth, Bombyx mori, which is moulded into a structure that supports and promotes tissue regeneration in the joint. The high tensile strength, flexibility and biocompatibility of silk-based materials make them an excellent prospect for structural implants, where the alternative is costly knee replacement surgery. Orthox’s lead product, FibroFix™ Cartilage, will target articular cartilage in the knee, and could be adapted for other articulating joints e.g., shoulder, ankle, hip and elbow or other human tissues. FibroFix™ Cartilage is currently undergoing preclinical assessment with first in human trials anticipated in late Q4 2021.

Important notice: This webinar recording is for information purposes only. Reliance on the information in this webinar recording, for the purpose of engaging in any investment activity, may expose an individual to a risk of losing all of the funds invested. The information disclosed in this webinar recording does not constitute, or should be considered as, an offer to buy or sell or solicitation of an offer to buy or sell any security or share.